Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363012 · ClinicalTrials.gov registry record · NA
Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT00363012: Completed NA study, sponsored by University of Washington.
NCT00363012 is a NA study that has completed, run by University of Washington. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00363012, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2. PURPOSE: This clinical trial is studying the immune response in patients who have undergone vaccine therapy for stage III or stage IV breast cancer that overexpresses HER2.
Interventions
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- OTHER flow cytometry
- BIOLOGICAL HER-2/neu intracellular domain protein
- OTHER Sterile water placement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-04 |
| Est. Completion | 2010-03 |
| Phase | NA |
What the finished NCT00363012 record still lists
NCT00363012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which biopsy is the first listed.
NCT00363012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00363012 about?
NCT00363012 is a clinical study titled "Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2". RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2. PURPOSE: This clinical trial is studying the immune response in patients who have undergone vaccine therapy for stage III o...
What is the current status of trial NCT00363012?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2006-04. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00363012?
The interventions under investigation include: biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), flow cytometry (OTHER), HER-2/neu intracellular domain protein (BIOLOGICAL), Sterile water placement (OTHER).
Who is sponsoring clinical trial NCT00363012?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00363012's enrollment target sits among peer trials
56 1262nd of 2000 higher than 737 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia